CClinicalTrials.gg
RecruitingNCT07382206SONEXUpdated Feb 2, 2026

Effect of Acute Exercise on Sleep Patterns in Patients With PLMS, Using a Wearable Device, Compared With a Control Group ( SONEX )

An interventional study of cardiopulmonary exercise test (CPET) and Cardiopulmonary Exercise Test (CPET) - Twice in Periodic Leg Movements, Excessive, Sleep-Related, sponsored by Associação Fundo de Incentivo à Pesquisa. Recruiting at 1 site in Brazil. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by Associação Fundo de Incentivo à Pesquisa · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 1 month after the study started (first participant enrolled Dec 2024, registered Jan 2026).
  • Started Dec 2024; still recruiting 1 year 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
22 Years and older
Sex
All
01

Study summary

The effects of chronic exercise on health promotion, improvement of quality of life, and reduction of the risk of developing chronic diseases such as obesity, diabetes mellitus, cardiovascular diseases, depression, and cancer are well established. In addition, the positive influence of exercise on sleep patterns and sleep quality is widely recognized. However, few studies have addressed the effects of a single session of physical exercise on the circadian cycle and sleep disorders.

Regarding Periodic Limb Movement Disorder (PLMD), which is characterized by periodic episodes of repetitive and highly stereotyped limb movements, the scientific literature indicates that the effects of a single session of intense exercise remain insufficiently explored. Therefore, the present study aims to investigate, through a controlled interventional study, the effects of acute exercise on the Periodic Limb Movements of Sleep (PLMS) index.

To this end, the study will recruit healthy participants as well as individuals with PLMS to perform acute exercise sessions, followed by a polysomnographic examination and a longitudinal observation period. Throughout the study, participants will use wearable and mobile devices to monitor their physiological patterns. In addition, questionnaires related to sleep, physical exercise, cognitive decline, and depression will be administered to better characterize the study population.

Thus, this study aims to generate evidence regarding the influence of acute exercise on sleep patterns in participants with PLMS, as well as to obtain data to support the development of algorithms related to sleep quality, including PLMS detection, which may be embedded in wearable or mobile devices in the future.

02

Conditions studied

  • Periodic Leg Movements, Excessive, Sleep-Related

Keywords

  • Polysomnography
  • sleep
  • Device
  • Periodic Limb Movements of Sleep
  • Cardiopulmonary Exercise Test
03

In context

Lead sponsor

Associação Fundo de Incentivo à Pesquisa is the lead sponsor of 22 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

General Inclusion Criteria:

  • Aged 22 years or older;
  • Self-reported habitual sleep of at least 5 consecutive hours per night. Specific Inclusion Criteria for the PLMS Group
  • Having a prior polysomnography (PSG) showing a PLMS index ≥ 15/h;
  • Screening PSG for participants without a PSG in the last 6 months showing a PLMS index ≥ 15/h.

Note: Efforts will be made to ensure that approximately 50% of the sample consists of participants with a PLMS index > 50/h. -

General Exclusion Criteria:

  • Pregnant or lactating individuals;
  • Presence of dermatological conditions or skin diseases such as vitiligo, lupus, atopic dermatitis, or tattoos on the wrist or fingers that could interfere with optical sensor readings from the smartwatch or smart ring;
  • Inability to attend the study PSG sessions;
  • Use of medications indicated for the treatment of sleep disorders;
  • Current or prior treatment for PLMS management;
  • Presence of implanted cardiac devices, such as pacemakers, cardioverter defibrillators, or cardiac resynchronization devices;
  • Prior diagnosis of chronic neurological, orthopedic, cardiac, pulmonary, or other clinical conditions that limit the ability to perform physical activity.

Specific Exclusion Criteria for the Control Group:

-Presence of sleep disorders identified on the screening PSG, such as: moderate to severe sleep apnea (apnea-hypopnea index [AHI] ≥ 15), insomnia with an Insomnia Severity Index (ISI) score above 14, or PLMS index > 15.-

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    PLM Group

    A single session of acute intense exercise will influence sleep-related biological parameters assessed by polysomnography, including the number of PLMS events.

    Procedure: Cardiopulmonary Exercise Test (CPET) - Twice

  • Experimental
    Control Group

    A single acute session of intense exercise will be reflected in sleep biological parameters measured by polysomnography, including the number of PLMS events.

    Procedure: cardiopulmonary exercise test (CPET)

Interventions

  • Procedurecardiopulmonary exercise test (CPET)

    The participant will perform a single session of acute exercise 4 hours prior to polysomnography. On the same day, shortly before the polysomnography, study questionnaires will be administered, and the study devices (watch and ring) will be placed on the participant to record electrophysiological sleep parameters in conjunction with the polysomnography. The following morning, participants will be discharged and will continue to use the devices and complete study questionnaires at home for seven consecutive days. After the seven-day period, participants will return to undergo the second and final polysomnography. On this day, prior to the polysomnography, participants will complete study questionnaires, and advanced glycation end-products (AGEs) will be measured using the AGEs device and the smartwatch.

  • ProcedureCardiopulmonary Exercise Test (CPET) - Twice

    The participant will undergo a single session of acute exercise (CPET) 4 hours prior to polysomnography (PSG). Before the PSG, study questionnaires will be administered, and the participant will wear study devices (smartwatch and smart ring) to collect sleep and physiological data during the night, in conjunction with the (PSG). The next day, participants will be discharged and begin a seven-day free-living period, during which they will continue using the devices at night. After this seven-day period, participants will return for a second PSG. On this day, prior to the PSG, participants will complete study questionnaires, and advanced glycation end-products (AGEs) will be measured using the AGE scanner device and the smartwatch. This description outlines the first block of the protocol. Following an interval of up to seven days to 3 weeks, the protocol will be repeated as described above, excluding the final PSG. This repetition constitutes the 2º block of the protocol.

06

What researchers measure

Primary outcomes

  1. Sleep parameters measured by polysomnography

    A single acute session of intense exercise will be reflected in sleep-related biological parameters measured by polysomnography, including the number of PLMS events. Furthermore, the exercise effect will also be compared between two different groups: individuals with PLMS and those without PLMS.

    Time frame: 7 days

07

Study locations

1 of 1 sites recruiting
  • CDEC Brasil
    São Paulo, São Paulo 04020060, Brazil
    • Magda Bignotto, PhD · Contact · magda.bignotto@cdecbrasil.com.br · 5511971547331
    • Suelen Oliveira da Rosa, BPharm · Contact · sueli.rosa@cdecbrasil.com.br · 551155790373
    • Erika Cristine Treptow, PhD · Principal investigator
    • Marlon Manhães Faes, MD · Sub investigator
    • Pedro Henrique Ribeiro, MD · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — The parties have agreed that the data will be shared with the study collaborator exclusively in anonymized form.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07382206
Lead sponsor
Associação Fundo de Incentivo à Pesquisa
Collaborators
Samsung Eletrônica da Amazônia Ltda
Responsible party
Sponsor
First posted
Feb 2, 2026
Start date
Dec 24, 2024
Primary completion
Apr 1, 2026 (estimated)
Completion
Apr 30, 2026 (estimated)
Last update
Feb 2, 2026

Study contacts

Magda Bignotto, PhD
Contact
magda.bignotto@cdecbrasil.com.br
5511971547331
Suelen Oliveira da Rosa, BPharm
Contact
suelen.rosa@cdecbrasil.com.br
551155790373
Erika Cristine Treptow, PhD
principal investigator · Instituto do Sono

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion